ABP 215 (Bevacizumab-awwb) 是一种 Bevacizumab (Bevacizumab (HY-P9906)) 生物类似药,是一种靶向VEGFA(VEGFR) 的人源化 IgG1 单克隆抗体。ABP 215 具有抗癌作用,可用于转移性结直肠癌 (mCRC) 研究。
生物活性 | ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanizedIgG1monoclonal antibody targetingVEGFA(VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectalcancer(mCRC) research[1][2]. |
体外研究 (In Vitro) | ABP 215 (Bevacizumab-awwb) 与 VEGF-A 结合,阻止 VEGF-A 与内皮细胞表面的 VEGF 受体结合,抑制内皮细胞增殖和新血管形成,从而导致肿瘤脉管系统正常化。
|
CAS 号 | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |